Safety, immunogenicity and kinetics of immune response to 7-valent pneumococcal conjugate vaccine in children with idiopathic nephrotic syndrome

Safety, immunogenicity and kinetics of 7-valent pneumococcal-conjugate vaccine (PCV7) immune response were evaluated in 33 children with idiopathic nephrotic syndrome (INS) and 16 controls. PCV7 was not associated with increased risk of relapse (RR = 0.80, p = 0.61). Serotype (PS)-specific antibodies increased in all subjects at 1 month (p < 0.01) with inferior immunogenicity for 3/7 PS in patients on immunomodulators (p < 0.02). Most patients retained protective antibodies at 12–14 months although at lower levels for 4/7 PS (p < 0.08). Different PS kinetics in INS suggests antibody monitoring and revaccination when necessary for protection from pneumococcocal infections.

► Safety and kinetics of immune response to PCV7 in children with INS in remission.
► PCV7 is safe and not associated with recurrence of INS.
► MMF and CyA immunomodulatory therapy affects PCV7 induced specific immunity.
► Protective antibodies persist at lower level at 12–14 months compared with controls.